A Phase 1 interventional study of [14C]HRS-8080 in Breast Cancer, sponsored by Shandong Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to female participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-08.
Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing HRS-8080 in Breast Neoplasms — 8 open to participants now, 8 under way, 3 of them phase 3. HRS-8080 · Breast Neoplasms.
Among the 11 studies testing HRS-8080 in Breast Neoplasms, this one is the 11th largest by enrollment, is one of 5 that started in 2026, is one of 4 in phase 1, and was the 7th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →8 of the 11 studies testing HRS-8080 in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–75 · Women only
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–75 · Women only
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–75 · Women only
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–75 · Women only
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–75 · Women only
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years to 70 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 4 · Phase 3 3
First in 2023; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 180 across the 11 interventional studies. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
This study is registered under Shandong Suncadia Medicine Co., Ltd., one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Shandong Suncadia Medicine Co., Ltd. is the lead sponsor of 87 studies on the registry; 39 are open to participants now.
53 studies in Breast Neoplasms by Jiangsu HengRui Medicine Co., Ltd.: 18 open now, 27 under way, 12 of them phase 3. Of 17 finished, 0 (0%) have results posted.
Among the 53 studies in Breast Neoplasms by Jiangsu HengRui Medicine Co., Ltd., this one is the 51st largest by enrollment, is one of 9 that started in 2026, is one of 19 in phase 1, and was the 45th registered.
Jiangsu HengRui Medicine Co., Ltd.’s Breast Neoplasms studies by the year they started, since 2011.
2 of the studies testing HRS-8080 in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07024173Phase 3Shandong Suncadia Medicine Co., Ltd.A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer | 2027-08 |
| NCT07876596Shandong Suncadia Medicine Co., Ltd.A Drug-Drug Interaction Study of Rifampicin and Oral HRS-8080 | 2027-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies testing HRS-8080 in Breast Neoplasms, from their registry updates:
Among Jiangsu HengRui Medicine Co., Ltd.’s 53 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This single-part, healthy volunteer study will try to identify how the test medicine is taken up, broken down and removed from the body. To help investigate this, the test medicine is radiolabelled, which means that the test medicine has a radioactive component (carbon-14) which helps us to track where the test medicine is in the body. The safety and tolerability of the test medicine will also be studied.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: [14C]HRS-8080
Subjects will receive single dose of orally \[14C\]HRS-8080.
The cumulative amount of HRS-8080 excreted.
Time frame: 0 hour to 360 hours.
Percentage of parent drug and its metabolite(s) relative to total radioactive exposure in plasma.
Time frame: 0 hour to 360 hours.
Percentage of administered dose excreted as parent drug and its metabolite(s) in urine.
Time frame: 0 hour to 360 hours.
Percentage of administered dose excreted as parent drug and its metabolite(s) in feces.
Time frame: 0 hour to 360 hours.
Maximum concentration (Cmax).
Pharmacokinetic parameters for total radioactivity in plasma.
Time frame: 0 hour to 336 hours.
Time of maximum concentration (Tmax).
Pharmacokinetic parameters for total radioactivity in plasma.
Time frame: 0 hour to 336 hours.
Area under the concentration-time curve (AUC).
Pharmacokinetic parameters for total radioactivity in plasma.
Time frame: 0 hour to 336 hours.
Elimination half-life (t1/2).
Pharmacokinetic parameters for total radioactivity in plasma.
Time frame: 0 hour to 336 hours.
Apparent clearance (CL/F).
Pharmacokinetic parameters for total radioactivity in plasma.
Time frame: 0 hour to 336 hours.
Apparent volume of distribution (Vz/F).
Pharmacokinetic parameters for total radioactivity in plasma.
Time frame: 0 hour to 336 hours.
Ratio of total radioactivity in whole blood to plasma.
Time frame: 0 hour to 360 hours.
Maximum concentration (Cmax).
Pharmacokinetic parameters for HRS-8080 and its metabolite(s) in plasma.
Time frame: 0 hour to 336 hours.
Time of maximum concentration (Tmax).
Pharmacokinetic parameters for HRS-8080 and its metabolite(s) in plasma.
Time frame: 0 hour to 336 hours.
Area under the concentration-time curve (AUC).
Pharmacokinetic parameters for HRS-8080 and its metabolite(s) in plasma.
Time frame: 0 hour to 336 hours.
Elimination half-life (t1/2).
Pharmacokinetic parameters for HRS-8080 and its metabolite(s) in plasma.
Time frame: 0 hour to 336 hours.
Apparent clearance (CL/F).
Pharmacokinetic parameters for HRS-8080 and its metabolite(s) in plasma.
Time frame: 0 hour to 336 hours.
Apparent volume of distribution (Vz/F).
Pharmacokinetic parameters for HRS-8080 and its metabolite(s) in plasma.
Time frame: 0 hour to 336 hours.
Adverse events (AEs).
Time frame: Day -7 to Day 23.
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jan 2026 to primary completion in Jan 2026, 0 months.
Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 0 months is below that.
Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HRS-8080
Shandong Suncadia Medicine Co., Ltd. →